Toxin for Tics: Practical Guidance for Clinicians from a Registry-Based Naturalistic Study.

IF 2.6 4区医学 Q2 CLINICAL NEUROLOGY

Movement Disorders Clinical Practice Pub Date : 2025-03-01 Epub Date: 2024-12-07 DOI:10.1002/mdc3.14296

Tamara Pringsheim, Davide Martino

{"title":"Toxin for Tics: Practical Guidance for Clinicians from a Registry-Based Naturalistic Study.","authors":"Tamara Pringsheim, Davide Martino","doi":"10.1002/mdc3.14296","DOIUrl":null,"url":null,"abstract":"Background: Botulinum toxin is a recommended treatment for tics. There is little practical guidance on the use of this treatment.Objectives: Our aim is to describe our experience using botulinum toxin injections for tics in adults. We provide information on tics treated, muscles injected, and dosages used to give practical guidance.Methods: We analyzed data from the Calgary Adult Tic Registry on tic severity, the tics and muscles injected, and dosages. We assessed treatment length, reasons for discontinuation, and concurrent medications.Results: Botulinum toxin was the most used medication for tics, received by 32 of 95 (33.7%) registry participants. Participants receiving botulinum toxin were significantly older and had significantly lower vocal tic severity and total tic severity. The most common motor tics treated were blinking, head turns, and shoulder raising. The mean length of treatment was 40.4 months.Conclusions: Botulinum toxin is an effective and well-tolerated treatment for adults with tics.","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":"353-357"},"PeriodicalIF":2.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11952939/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Movement Disorders Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/mdc3.14296","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Botulinum toxin is a recommended treatment for tics. There is little practical guidance on the use of this treatment.

Objectives: Our aim is to describe our experience using botulinum toxin injections for tics in adults. We provide information on tics treated, muscles injected, and dosages used to give practical guidance.

Methods: We analyzed data from the Calgary Adult Tic Registry on tic severity, the tics and muscles injected, and dosages. We assessed treatment length, reasons for discontinuation, and concurrent medications.

Results: Botulinum toxin was the most used medication for tics, received by 32 of 95 (33.7%) registry participants. Participants receiving botulinum toxin were significantly older and had significantly lower vocal tic severity and total tic severity. The most common motor tics treated were blinking, head turns, and shoulder raising. The mean length of treatment was 40.4 months.

Conclusions: Botulinum toxin is an effective and well-tolerated treatment for adults with tics.

查看原文本刊更多论文

毒素抽搐：临床医生从注册为基础的自然研究的实践指导。

背景：肉毒杆菌毒素是抽搐的推荐治疗方法。关于这种治疗方法的实用指导很少。目的：我们的目的是描述我们使用肉毒杆菌毒素注射治疗成人抽搐的经验。我们提供抽搐治疗、肌肉注射和剂量方面的信息，并给出实际指导。方法：我们分析了卡尔加里成人抽动登记的数据，包括抽动严重程度、抽动和注射肌肉以及剂量。我们评估了治疗时间、停药原因和并发用药情况。结果：肉毒杆菌毒素是治疗抽搐最常用的药物，95名登记参与者中有32名（33.7%）服用了肉毒杆菌毒素。接受肉毒杆菌毒素治疗的参与者明显年龄较大，声音抽动严重程度和总抽动严重程度明显较低。最常见的运动性抽搐是眨眼、头部转动和耸肩。平均治疗时间为40.4个月。结论：肉毒杆菌毒素治疗成人抽动症有效且耐受性良好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Movement Disorders Clinical Practice CLINICAL NEUROLOGY-

CiteScore

4.00

自引率

7.50%

发文量

218

期刊介绍： Movement Disorders Clinical Practice- is an online-only journal committed to publishing high quality peer reviewed articles related to clinical aspects of movement disorders which broadly include phenomenology (interesting case/case series/rarities), investigative (for e.g- genetics, imaging), translational (phenotype-genotype or other) and treatment aspects (clinical guidelines, diagnostic and treatment algorithms)